Continuous glucose monitoring for people with diabetes on peritoneal dialysis
Official title: Continuous Glucose Monitoring as a Strategy to Optimize Metabolic Control in Patients With Diabetes on Peritoneal Dialysis Therapy Entitled to the IMSS
Run by Coordinación de Investigación en Salud, Mexico · NCT06069518 · Data updated 2026-11-12
This study tests whether continuous glucose monitoring can help tailor insulin type, dose, and timing for adults with type 2 diabetes on automated peritoneal dialysis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years to 70 Years |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Coordinación de Investigación en Salud, Mexico Government |
| Locations | 2 sites (Mexico City, Mexico City and 1 other locations) |
| Status | Recruiting |
| Started | June 1, 2024 |
| Main results expected | March 31, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT06069518 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 40 with type 2 diabetes and diabetic nephropathy who are on automated peritoneal dialysis for at least three months, with high or high-average peritoneal transport.
✕Probably not a fit
Patients who do not meet the inclusion criteria or have contraindications (e.g., active cancer, recent cardiovascular or infectious hospitalization, pregnancy) may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a cross-sectional, non-interventional study of adults with type 2 diabetes on automated peritoneal dialysis who have high or high-average peritoneal transport characteristics. It uses continuous glucose monitoring to describe glucose patterns over 24 hours and to explore how insulin regimens relate to those patterns. The goal is to inform better glycemic management during dialysis and potentially reduce complications. Participants are adults over 40 with diabetic nephropathy, on PD for at least three months, and without major acute illnesses or certain co-morbidities. The study is led by Coordinación de Investigación en Salud in Mexico, with Baxter Healthcare as a collaborator, at two Mexico City hospitals.
Why it matters
Potential benefit: If successful, the findings could help personalize insulin strategies for dialysis patients and improve metabolic control.
How similar studies have gone: Prior work in this area supports the value of continuous glucose monitoring for detecting glycemic patterns in complex care settings, though specific data in this exact population are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of diabetic nephropathy. * Insulin-dependent diabetes mellitus requiring insulin for glycemic control. * At least three months of peritoneal dialysis treatment. Exclusion Criteria: * Positive serology for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). * Acute medical complications. * Hospitalization for cardiovascular, metabolic, or infectious conditions within the month preceding enrollment. * Cancer. * Pregnancy. * Allergy.
Where it's running
-
Hospital 1A Venados
Mexico City, Mexico City, Mexico Recruiting -
Hospital General Regional 1 "Carlos Mc Gregor"
Mexico City, Mexico City, Mexico Recruiting
Study contacts
- Study coordinator: Miguel Angel Cuevas Budhart A Cuevas-Budhart, MSc, PhD
- Email: angel_budhart@hotmail.com
- Phone: +525559443541
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proliverenol for liver fat and insulin resistance in type 2 diabetes
This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes
This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.
-
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes
This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin
This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.